

Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York

Eli S. Rosenberg PhD¹, James M. Tesoriero PhD², Elizabeth M. Rosenthal MPH¹, Rakkoo Chung PhD², Meredith A. Barranco MPH¹, Linda M. Styer PhD³, Monica M. Parker PhD³, Shu-Yin John Leung MA², Johanne E. Morne MS², David Holtgrave PhD¹, Dina Hoefler PhD², Jessica Kumar DO², Tomoko Udo PhD¹, Brad Hutton MPH², Howard A. Zucker, MD²

1. University at Albany School of Public Health, State University of New York, Rensselaer NY
2. New York State Department of Health, Albany NY
3. Wadsworth Center, New York State Department of Health, Albany NY

Supplemental material

Contents

Validation Studies.....	2
Part 1. Assay Specificity	2
eTable 1. Cutoff assay using normal human dry blood spots (DBS)	2
eTable 2. Serum collected from patients with antibodies to the indicated non-respiratory agents tested for reactivity to the SARS CoV-1 N protein.....	2
eTable 3. Serum collected from patients diagnosed with the indicated Non-COVID 19 respiratory agents tested for reactivity to the SARS CoV-1 N and SARS CoV-2 N protein.....	3
Part 2. Assay Sensitivity.....	3
eTable 4. Assay results for a set of 232 individuals with self-reported positive PCR results, with median (IQR) days from symptom onset to DBS collection.....	3
Part 3 – SARS CoV-1 N vs. SARS CoV-2 N assay comparison	4
eFigure. Comparison of MFI values for DBS samples tested by the SARS CoV-1 N versus SARS CoV-2 N assay.....	4
eTable 5. Comparison of qualitative results of the same samples tested by the SARS CoV-1 N vs SARS CoV-2 N assay.....	4
Sensitivity analyses for cumulative incidence and percent diagnosed.....	5
eTable 6. Reactivity and test-characteristic adjusted cumulative incidence of COVID-19, overall and by demographic factors and region: sensitivity 92.1%, specificity 96.1%	5
eTable 7. Reactivity and test-characteristic adjusted cumulative incidence of COVID-19, overall and by demographic factors and region: sensitivity 83.7%, specificity 100%	6
eTable 8. Estimated percentage of SARS-COV-2 infections diagnosed by last plausible diagnosis date	7

Validation Studies

Part 1. Assay Specificity

eTable 1. Cutoff assay using normal human dry blood spots (DBS)

Normal DBS collected prior to December 2019 were tested to establish background levels of reactivity to the SARS CoV-1 N and SARS CoV-2 N protein. Specificity for primary analyses was based on the mean of observed reactivity to each protein (99.5%, 100% respectively), which was 99.75%.

Assay	Number tested	Number > Mean + 3 SD	Number > Mean + 6 SD	Specificity	95% CI
SARS CoV-1 N	196	5	1	195/196 = 99.5%	98.5-100%
SARS CoV-2 N	92	2	0	92/92 = 100%	96.1-100%

eTable 2. Serum collected from patients with antibodies to the indicated non-respiratory agents tested for reactivity to the SARS CoV-1 N protein.

Analyte	Number tested	Number > Mean + 3 SD	Number > Mean + 6 SD
Antinuclear antibodies	3	0	0
Chikungunya virus	3	0	0
Dengue virus	3	0	0
Enterovirus	2	0	0
Epstein Barr Virus	3	0	0
Hepatitis C virus	3	0	0
Herpes Simplex virus	3	0	0
HIV	3	0	0
Measles	6	0	0
Mumps	6	0	0
Parvovirus B19	4	0	0
Rheumatoid Factor	3	0	0
Rubella	3	0	0
Syphilis	3	1	1
Varicella Zoster virus	3	0	0
West Nile Virus	3	0	0
Zika virus	3	0	0
TOTAL	57	1	1

eTable 3. Serum collected from patients diagnosed with the indicated Non-COVID 19 respiratory agents tested for reactivity to the SARS CoV-1 N and SARS CoV-2 N protein.

Analyte	SARS CoV-1 N			SARS CoV-2 N		
	Number tested	Number > Mean + 3 SD	Number > Mean + 6 SD	Number tested	Number > Mean + 3 SD	Number > Mean + 6 SD
Human coronavirus NL63	6	0	0	4	0	0
Human coronavirus OC43	2	0	0	2	0	0
Human parainfluenza virus	1	0	0	1	0	0
Influenza	6	0	0	15	1	0
Metapneumovirus	6	0	0	6	0	0
Rhinovirus	7	0	0	6	0	0
TOTAL	28	0	0	34	1	0

Part 2. Assay Sensitivity


eTable 4. Assay results for a set of 232 individuals with self-reported positive PCR results, with median (IQR) days from symptom onset to DBS collection

<u>Result</u>	<u>#</u>	<u>Median days post symptom onset</u>	<u>IQR</u>
Non-Reactive	21	33	28-37
Indeterminate	7	30	28-34
Reactive	204	35	30-40
TOTAL	232		

Based on 204 of 232 reactive, estimate sensitivity was 87.9% (exact 95% CI: [83.7-92.1%])

Part 3 – SARS CoV-1 N vs. SARS CoV-2 N assay comparison

eFigure. Comparison of MFI values for DBS samples tested by the SARS CoV-1 N versus SARS CoV-2 N assay



eTable 5. Comparison of qualitative results of the same samples tested by the SARS CoV-1 N vs SARS CoV-2 N assay.

		SARS CoV-2 N			TOTAL
		R	IND	NR	
SARS CoV-1 N	R	17	0	0	17
	IND	0	0	0	0
	NR	5	6	145	156
	TOTAL	22	6	145	173

Concordance 162/173 94% Results match exactly (NR-NR, IND-IND, R-R)
 Discordance 5/173 3% Reactive = Non-reactive, Non-reactive = Reactive

Sensitivity analyses for cumulative incidence and percent diagnosed

eTable 6. Reactivity and test-characteristic adjusted cumulative incidence of COVID-19, overall and by demographic factors and region: sensitivity 92.1%, specificity 96.1%

	Reactivity		Test-characteristic adjusted estimated cumulative incidence				
	Unweighted # Reactive / Total Sample	Weighted percent	%	(95% CI)	Infection- experienced adults ^a	(95% CI)	% of Infection- experienced adults
Overall	1,887/15,101	12.5	9.8	(9.1-10.5)	1,494,700	(1,391,800-1,597,600)	100.0
Sex							
Male	918/6,635	13.2	10.6	(9.6-11.6)	769,200	(695,000-843,400)	51.5%
Female	969/8,466	11.9	9.1	(8.2-10.0)	724,900	(653,700-796,200)	48.5%
Race/Ethnicity							
Hispanic or Latino	757/2,735	25.8	24.9	(22.9-26.9)	661,300	(608,400-714,100)	24.9
NH-White	623/9,545	7.3	3.9	(3.2-4.5)	344,500	(286,500-402,500)	3.9
NH-Black/African American	388/1,913	18.0	15.9	(13.8-18.1)	337,800	(292,700-382,900)	15.9
NH-Asian	75/629	11.1	8.2	(5.2-11.1)	106,600	(67,800-145,500)	8.2
NH-Multi/Other	44/279	10.7	7.7	(2.2-13.2)	25,100	(7,300-43,000)	7.7
Age group							
18-34	377/3,151	13.0	10.4	(8.9-11.9)	484,900	(414,700-555,100)	10.4
35-44	334/2,628	13.7	11.1	(9.4-12.7)	269,100	(229,200-308,900)	11.1
45-54	479/3,345	14.3	11.8	(10.3-13.2)	312,500	(274,300-350,600)	11.8
55+	697/5,977	10.9	7.9	(7.0-8.9)	435,900	(384,000-487,800)	7.9
Region							
New York City ^b	1,319/5,946	20.2	18.5	(17.2-19.7)	1,221,700	(1,139,100-1,304,300)	**
Westchester/ Rockland Counties	134/980	14.4	11.9	(9.0-14.8)	115,400	(87,500-143,400)	**
Long Island ^c	241/2,074	11.9	9.0	(7.2-10.9)	198,800	(157,900-239,700)	**
Rest of NYS ^{d, e}	193/6,101	3.4	**	****	**	****	**

- a. Stratified estimates may not exactly sum to total due to rounding and differences between weighting scheme and non-institutionalized population totals
- b. Boroughs of Bronx, Brooklyn, Manhattan, Queens, Staten Island
- c. Nassau and Suffolk Counties
- d. Albany, Allegany, Broome, Cattaraugus, Cayuga, Chautauqua, Chemung, Chenango, Clinton, Columbia, Cortland, Delaware, Dutchess, Erie, Essex, Franklin, Fulton, Genessee, Greene, Hamilton, Herkimer, Jefferson, Lewis, Livingston, Madison, Monroe, Montgomery, Niagara, Oneida, Onondaga, Ontario, Orange, Orleans, Oswego, Otsego, Putnam, Rensselaer, St. Lawrence, Saratoga, Schenectady, Schoharie, Schuyler, Seneca, Steuben, Sullivan, Tioga, Tompkins, Ulster, Warren, Washington, Wayne, Wyoming, Yates counties
- e. Estimated values for Rest of NYS are negative, due to antibody prevalence < 1 - specificity (observed results may be dominated by false positives). True cumulative incidence is greater than 0, as evidence by diagnosed cases, rendering study-based cumulative incidence inestimable under these test characteristics. Values that cannot be estimated are indicated with ** in table.

eTable 7. Reactivity and test-characteristic adjusted cumulative incidence of COVID-19, overall and by demographic factors and region: sensitivity 83.7%, specificity 100%

	Reactivity		Test-characteristic adjusted estimated cumulative incidence				
	Unweighted # Reactive / Total Sample	Weighted percent	%	(95% CI)	Infection- experienced adults ^a	(95% CI)	% of Infection- experienced adults
Overall	1,887/15,101	12.5	15.0	(14.3-15.7)	2,286,600	(2,178,200-2,395,100)	100.0
Sex							
Male	918/6,635	13.2	15.8	(14.7-16.9)	1,149,500	(1,071,300-1,227,600)	50.3
Female	969/8,466	11.9	14.2	(13.3-15.2)	1,136,600	(1,061,500-1,211,700)	49.7
Race/Ethnicity							
Hispanic or Latino	757/2,735	25.8	30.9	(28.8-33.0)	820,700	(765,000-876,400)	36.2
NH-White	623/9,545	7.3	8.8	(8.1-9.4)	775,900	(714,800-837,000)	34.2
NH-Black/African American	388/1,913	18.0	21.5	(19.2-23.7)	454,700	(407,200-502,200)	20.1
NH-Asian	75/629	11.1	13.3	(10.1-16.4)	173,300	(132,300-214,300)	7.6
NH-Multi/Other	44/279	10.7	12.8	(7.0-18.6)	41,600	(22,800-60,500)	1.8
Age group							
18-34	377/3,151	13.0	15.6	(14.0-17.2)	729,100	(655,100-803,100)	31.8
35-44	334/2,628	13.7	16.3	(14.6-18.1)	396,700	(354,700-438,700)	17.3
45-54	479/3,345	14.3	17.1	(15.6-18.6)	452,800	(412,700-493,000)	19.7
55+	697/5,977	10.9	13.0	(12.0-14.0)	716,000	(661,300-770,600)	31.2
Region							
New York City ^b	1,319/5,946	20.2	24.1	(22.8-25.4)	1,595,700	(1,508,700-1,682,800)	69.5
Westchester/ Rockland Counties	134/980	14.4	17.2	(14.2-20.2)	166,800	(137,400-196,300)	7.3
Long Island ^c	241/2,074	11.9	14.2	(12.2-16.1)	312,200	(269,100-355,400)	13.6
Rest of NYS ^d	193/6,101	3.4	4.0	(3.4-4.6)	220,200	(186,700-253,700)	9.6

- a. Stratified estimates may not exactly sum to total due to rounding and differences between weighting scheme and non-institutionalized population totals
- b. Boroughs of Bronx, Brooklyn, Manhattan, Queens, Staten Island
- c. Nassau and Suffolk Counties
- d. Albany, Allegany, Broome, Cattaraugus, Cayuga, Chautauqua, Chemung, Chenango, Clinton, Columbia, Cortland, Delaware, Dutchess, Erie, Essex, Franklin, Fulton, Genessee, Greene, Hamilton, Herkimer, Jefferson, Lewis, Livingston, Madison, Monroe, Montgomery, Niagara, Oneida, Onondaga, Ontario, Orange, Orleans, Oswego, Otsego, Putnam, Rensselaer, St. Lawrence, Saratoga, Schenectady, Schoharie, Schuyler, Seneca, Steuben, Sullivan, Tioga, Tompkins, Ulster, Warren, Washington, Wayne, Wyoming, Yates counties

eTable 8. Estimated percentage of SARS-COV-2 infections diagnosed by last plausible diagnosis date

	Estimated infection-experienced adults		Diagnosed adults through May 8, 2020			
	Adults	95% CI	Diagnoses	% diagnosed	(95% CI)	% of diagnosed adults
Overall	2,139,300	(203,5800-2,242,800)	335,770	15.7	(15.0-16.5)	100.0
Sex						
Male	1,076,500	(1,001,900-1,151,100)	172,238	16.0	(15.0-17.2)	51.6
Female	1,062,200	(990,500-1,133,800)	161,799	15.2	(14.3-16.3)	48.4
Unknown			1,733			
Age						
18-34	682,600	(612,000-753,200)	71,427	10.5	(9.5-11.7)	21.9
35-44	371,800	(331,700-411,900)	54,792	14.7	(13.3-16.5)	16.8
45-54	424,700	(386,400-463,100)	61,054	14.4	(13.2-15.8)	18.8
55+	667,800	(615,600-719,900)	138,312	20.7	(19.2-22.5)	42.5
Missing/Invalid			851			
Region						
New York City ^a	1,504,400	(1,421,300-1,587,500)	187,623	12.5	(11.8-13.2)	55.9
Westchester/ Rockland Counties	156,500	(128,400-184,600)	39,967	25.5	(21.7-31.1)	11.9
Long Island ^b	291,800	(250,600-332,900)	75,100	25.7	(22.6-30.0)	22.4
Rest of State ^c	194,600	(162,600-226,600)	33,080	17.0	(14.6-20.3)	9.9

- a. Boroughs of Bronx, Brooklyn, Manhattan, Queens, Staten Island
- b. Nassau and Suffolk Counties
- c. Albany, Allegany, Broome, Cattaraugus, Cayuga, Chautauqua, Chemung, Chenango, Clinton, Columbia, Cortland, Delaware, Dutchess, Erie, Essex, Franklin, Fulton, Genessee, Greene, Hamilton, Herkimer, Jefferson, Lewis, Livingston, Madison, Monroe, Montgomery, Niagara, Oneida, Onondaga, Ontario, Orange, Orleans, Oswego, Otsego, Putnam, Rensselaer, St. Lawrence, Saratoga, Schenectady, Schoharie, Schuyler, Seneca, Steuben, Sullivan, Tioga, Tompkins, Ulster, Warren, Washington, Wayne, Wyoming, Yates counties